Phase I safety and antigenicity of TA-GW: A recombinant HPV6 L2E7 vaccine for the treatment of genital warts

Vaccine

Volumn 17, Issue 1, 1999, Pages 40-49

  Thompson, H S G ^a   Davies, M L ^a   Holding, F P ^a   Fallon, R E ^a   Mann, A E ^a   O'Neill, T ^a   St Clair Roberts, J ^a  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Condylomata acuminata; Genital warts; HPV; Immunotherapy; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ANTIBODY; GAMMA INTERFERON; HUMAN PAPILLOMA VIRUS 6 VACCINE; HYBRID PROTEIN; INTERLEUKIN 5; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGENICITY; ARTICLE; CLINICAL TRIAL; CONDYLOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; VACCINATION; WART VIRUS;

ADULT; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CONDYLOMATA ACUMINATA; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INTERFERON TYPE II; INTERLEUKIN-5; LYMPHOCYTE ACTIVATION; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0032889347     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00146-7     Document Type: Article

References (36)

1. Shah KV, Howley PM, 1990. Papillomaviruses. In: Fields, B.N., Knipe, D.M. (Eds.), Virology, 2nd ed. Raven Press, New York, Chapter 59, pp. 1651-1676.
2. Sexually transmitted diseases quarterly report: genital warts and genital herpes simplex virus infection in England and Wales. Communicable Disease Report 1997, 7, 310-312.
3. Stone K.M. Human papillomavirus infection and genital warts: update on epidemiology and treatment. Clin. Infect. Dis. 20 (suppl. 1):1995;S91-S97.
4. Koutsky L.A. Epidemiology of genital human papillomavirus infection. Am. J. Med. 102(5A):1997;3-8.
5. Gross, G., 1995. In: Mindel, A. (Ed.), Genital Warts Human Papillomavirus Infection. Edward Arnold, London, Chapter 9, pp. 198-236.
6. Beutner K.R., Ferenczy A. Therapeutic approaches to genital warts. Am. J. Med. 102(5A):1997;28-37.
7. Biberstein H. Immunization therapy of warts. Arch. Dermat. Syph. 50:1944;12.
8. Powell L.C., Pollard M., Jinkins J.L. Treatment of condyloma acuminata by autogenous vaccine. South. Med J. 63:1970;202-205.
9. Abcarian H., Sharon N. Long-term effectiveness of the immunotherapy of anal condyloma acuminatum. Dis. Colon Rectum. 25:1982;648-651.
10. Malison M.D., Morris R., Jones L.W. Autogenous vaccine therapy for condyloma acuminatum. Br. J. Vener. Dis. 58:1982;62-65.
11. Wiltz O.H., Torregrosa M., Wiltz O. Autogenous vaccine: the best therapy for perianal condyloma acuminata. Dis. Colon Rectum. 38:1995;838-841.
12. Coleman N., Birley H.D.L., Renton A.M.et al. Immunological events in regressing genital warts. Am. J. Clin. Pathol. 102:1994;768-774.
13. Scarpini CG, Coleman N, Hanna NF, et al. Cytokine profile in regressing and non-regressing HPV infected genital warts. Submitted for publication.
14. Viac J., Chardonnet Y., Euvard S., Schmitt D. Epidermotropism of T cells correlates with intracellular adhesion molecule (ICAM1) expression in human papilloma virus induced lesions. J. Pathol. 168:1992;301-306.
15. Coleman N., Greenfield I.M., Hare J., Kruger-Gray H., Chain B.M., Stanley M.A. Characterization and functional analysis of the expression of intercellular adhesion molecule-1 in human papillomavirus-related disease of cervical keratinocytes. Am. J. Pathol. 143:1993;355-367.
16. Coleman N., Stanley M.A. Analysis of HLA-DR expression on keratinocytes in cervical neoplasia. Int. J. Cancer. 56:1994;314-319.
17. Petry K.U., Scheffel D., Bode U.et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int. J. Cancer. 57:1994;836-840.
18. Chirgwin K.D., Feldman J., Augenbraun M., Landesman S., Minkoff H. Incidence of venereal warts in human immunodeficiency virus-infected and uninfected women. J. Infect. Dis. 172:1995;235-238.
19. Jarrett W.F.H., Smith K.T., O'Neill B.W.et al. Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins. Virology. 184:1991;33-42.
20. Campo M.S., Grindlay G.J., O'Neill B.W., Chandrachud L.M., McGarvie G.M., Jarrett W.F. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J. Gen. Virol. 74:1993;945-953.
21. Selvakumar R., Borenstein L.A., Lin Y-L., Ahmed R., Wettstein F.O. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J. Virol. 69:1995;602-605.
22. Greer C.E., Wheeler C.M., Ladner M.B.et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J. Clin. Microbiol. 33:1995;2058-2063.
23. Schwarz E.et al. DNA sequence and organisation of genital human papillomavirus type 6b. EMBO J. 2:1983;2341-48.
24. Dartman K., Schwarz E., Gissman L., zur Hausen H. The nucleotide sequence and genome organisation of human papillomavirus type 11. Virology. 151:1986;124-130.
25. Heinzel P.A., Chan S-Y., Ho L.et al. Variation of human papillomavirus type 6 (HPV-6) and HPV-11 genomes sampled throughout the world. J. Clin. Microbiol. 33(HPV-6):1995;1746-1754.
26. Lindblad EB, 1995. Aluminium adjuvants. In: Stewart-Tull DES (Ed.), The Theory and Practical Application of Adjuvants. John Wiley, Chichester, p. 21.
27. Bretscher P.A., Wei G., Menon J.N., Bielefeldt-Ohmann H. Establishment of stable, cell mediated immunity that makes 'susceptible' mice resistant to Leishmania major. Science. 257:1992;539-42.
28. Shearer G.M., Clerici M. Vaccine strategies: selective elicitation of cellular or humoral immunity? Trends Biotech. 15:1997;106-109.
29. Biberstein H. Vershue über Immunotherapie der Warzen und Kondylome. Klin. Wchnschr. 4:1925;638-639.
30. Biberstein H. Die Immunotherapie der Warzen und Kondylome. Klin. Wchnschr. 11:1932;1021-1025.
31. Jarrett W.F.H., O'Neill B.W., Gaukroger J.M., Smith K.T., Laird H.M., Campo M.S. Studies on the vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types. Veterinary Record. 126:1990;473-475.
32. Breitburd F., Kirnbauer R., Hubbert N.L.et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69:1995;3959-3963.
33. Suzich J.A., Ghim S-J., Palmer-Hill F.J.et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA. 92:1995;11553-11557.
34. Sterling JC, Thompson HSG, Giddings LK, et al. Immunotherapy with an HPV6 L2E7 fusion protein induces clearance of cutaneous warts in a subset of individuals. Submitted for publication.
35. Bal V., McIndoe A., Denton G.et al. Antigen presentation by keratinocytes induces tolerance in human T cells. Eur. J. Immunol. 20:1990;1893-1897.
36. Thompson HSG, Davies ML, Watts MJ, et al. Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A. Submitted for publication.